Biogen Inc. (BIIB)

283.75
4.06 1.45
NASDAQ : Health Technology
Prev Close 279.69
Open 277.14
Day Low/High 276.65 / 284.00
52 Wk Low/High 244.28 / 370.57
Volume 1.36M
Avg Volume 1.76M
Exchange NASDAQ
Shares Outstanding 211.01M
Market Cap 58.59B
EPS 11.90
P/E Ratio 19.83
Div & Yield N.A. (N.A)

Latest News

Video: Jim Cramer on Tesla, Biogen, Celgene and Groupon

Video: Jim Cramer on Tesla, Biogen, Celgene and Groupon

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending stocks from the floor of the New York Stock Exchange.

Stealth Rally: Cramer's 'Mad Money' Recap (Thursday 5/10/18)

Stealth Rally: Cramer's 'Mad Money' Recap (Thursday 5/10/18)

Take one part great earnings and one part tremendous skepticism, add in low inflation and you end up with this astonishing stealth rally. Jim Cramer explains it.

What to Expect From Trump's Speech on Drug Prices on Friday

What to Expect From Trump's Speech on Drug Prices on Friday

Since taking office, President Trump has talked big on reining in drug prices, but the administration's lack of action leaves most expecting a May 11 speech that tastes like a nothing burger.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALOT, AMOV, AMX, ARE, BIIB, BSM, DAN, DO, FUL, GIGM, JD, NGVT, OIS, WLL Downgrades: EQT, IVAC, PTNR, WP Initiations: ICCH Read on to get TheStreet Quant Ratings' detailed report:

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer and our other experts discus China and tariffs, the 10 year nearing 3%, technical analysis, and biotech stocks.

Here's My Take on Biotech Stocks

Here's My Take on Biotech Stocks

I think M&A activity will pick up markedly going forward across the industry.

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.

AbbVie Once Again Settles to Protect Humira Franchise From Biosimilars

AbbVie Once Again Settles to Protect Humira Franchise From Biosimilars

The company will not need to worry about Biogen and Samsung Bioepis launching a biosimilar to challenge the reign of its blockbuster arthritis drug until 2023 after the three companies settled patent actions.

Biogen And Samsung Bioepis Agree To Settlement With AbbVie Allowing Commercialization Of IMRALDI™ (Adalimumab Biosimilar) In Europe

Biogen And Samsung Bioepis Agree To Settlement With AbbVie Allowing Commercialization Of IMRALDI™ (Adalimumab Biosimilar) In Europe

Biogen Inc. (Nasdaq: BIIB) and its partner Samsung Bioepis announced today an agreement with AbbVie (NYSE: ABBV) for the commercialization of IMRALDI, a biosimilar referencing HUMIRA® (adalimumab).

Biogen To Report First Quarter 2018 Financial Results On April 24, 2018

Biogen To Report First Quarter 2018 Financial Results On April 24, 2018

Biogen Inc. (NASDAQ:BIIB) today announced it will report first quarter 2018 financial results on Tuesday, April 24, 2018, before the financial markets open.

Biogen Is In a Downtrend With Further Risk Ahead

Biogen Is In a Downtrend With Further Risk Ahead

Charts are signalling more trouble ahead for the stock.

Pfizer CEO Ian Read Gets 61% Raise to Keep Him From Considering Retirement

Pfizer CEO Ian Read Gets 61% Raise to Keep Him From Considering Retirement

Pfizer's CEO Ian Read could make almost $28 million in the next year to keep him from retiring. Strangely enough, he may earn it given the healthcare and political environment.

Biogen To Present At The 2018 Advances In Alzheimer's And Parkinson's Therapies (AAT-AD/PD) Focus Meeting

Biogen To Present At The 2018 Advances In Alzheimer's And Parkinson's Therapies (AAT-AD/PD) Focus Meeting

Biogen (Nasdaq: BIIB) will present data from its portfolio of investigational therapies for people with neurodegenerative diseases at the Advances in Alzheimer's and Parkinson's Therapies (AAT-AD/PD) Focus Meeting in...

Biogen To Present At The Advances In Alzheimer's And Parkinson's Therapies, An AAT-AD/PD Focus Meeting

Biogen To Present At The Advances In Alzheimer's And Parkinson's Therapies, An AAT-AD/PD Focus Meeting

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Advances in Alzheimer's and Parkinson's Therapies, an AAT-AD/PD Focus Meeting.

New Data Presented At MDA Clinical Conference Show Benefit In Motor Function For Infants, Teens And Young Adults Treated With SPINRAZA® (nusinersen)

New Data Presented At MDA Clinical Conference Show Benefit In Motor Function For Infants, Teens And Young Adults Treated With SPINRAZA® (nusinersen)

Biogen (Nasdaq: BIIB) today announced new interim Phase 2 results from NURTURE, the ongoing open-label, single-arm study evaluating the efficacy and safety of SPINRAZA ® (nusinersen) among pre-symptomatic...

Biogen To Acquire From Pfizer First-in-Class Phase 2b Ready Asset For Cognitive Impairment Associated With Schizophrenia

Biogen To Acquire From Pfizer First-in-Class Phase 2b Ready Asset For Cognitive Impairment Associated With Schizophrenia

Biogen Inc. (Nasdaq: BIIB) announced today an agreement to acquire from Pfizer Inc.

Tempur Sealy Is Lying Down, Plus 4 Other Stocks That Look Good Short

TPX, WR, GOV, BIIB and SRE were all recently were downgraded by TheStreet's Quant Ratings service.

20 Stock Picks to Weather Any Storm From Trade Wars to Fed Rate Hikes

20 Stock Picks to Weather Any Storm From Trade Wars to Fed Rate Hikes

Worry abounds on Wall Street this week. Do you know which stocks have the lowest exposure to developments from Washington?

Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal Of Marketing Authorizations For ZINBRYTA® (daclizumab) For Relapsing Multiple Sclerosis

Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal Of Marketing Authorizations For ZINBRYTA® (daclizumab) For Relapsing Multiple Sclerosis

Biogen (Nasdaq:BIIB) and AbbVie (NYSE:ABBV) today announced the voluntary worldwide withdrawal of ZINBRYTA for relapsing multiple sclerosis.

Biogen To Present At The Cowen And Company 38th Annual Health Care Conference

Biogen To Present At The Cowen And Company 38th Annual Health Care Conference

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Cowen and Company 38 th Annual Health Care Conference.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AC, BJRI, SUN, UNT Downgrades: AAC, BELFA, BIIB, BMCH, EIX, GXP, KMX, LAWS, LUK, MUX, RPXC, TPX, VDSI, WR Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.

Biogen Reports Top-Line Results From Phase 2b Study Of Natalizumab In Acute Ischemic Stroke

Biogen Reports Top-Line Results From Phase 2b Study Of Natalizumab In Acute Ischemic Stroke

Biogen (Nasdaq: BIIB) announced today that in the Phase 2b dose-ranging ACTION 2 study in individuals with acute ischemic stroke (AIS), natalizumab did not demonstrate improvement in clinical outcomes compared to placebo.

TheStreet Quant Rating: B- (Buy)